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A peptide inhibiting either corpuscolate or purified PKC has been identified from microsomes of PHA-activated human PBMC but it is not 
detectable m microsomes of resting PBMC. The peptide was obtained from a microsomal preparation in an oligomeric form that could be 
transformed mto a monomeric form by /?-MSH. The active peptide (IN) was retained on a PC-l 1 chromatographic column and could be eluted 
with NaCl. IN is ineffective on PKC-dependent protamme phosphorylation of protamme and on Ca” and phospholipid-independent activity 
generated by mild hydrolysis with trypsin of PKC. Ca” bmdmg is permissive for IN activity IN inhibits particulate PKC in PHA-activated PBMC, 
but is ineffective after TPA activation. All these data indicate that IN acts at the regulatory domain of PKC. 
PKC: Inhibitor: Regulatory domam 
1. INTRODUCTION 
Protein kinase C belongs to the class of second mes- 
senger-dependent protein kinases and plays a key role 
in extracellular signal transduction, cell proliferation 
and cell differentiation [1,2]. At least 10 molecular sub- 
species of PKC have been described, with differential 
tissue expression, specific intracellular localization and 
distinct enzymological characteristics [3]. PKC is made 
up of a regulatory and a catalytic domain; the first 
contains the Ca2’-dependent, phospholipid- and DAG- 
binding site, and the second, the ATP-binding site. One 
of the most outstanding characteristics of PKC is that 
it is physiologically active only when located in the 
plasma membrane, i.e. when it is associated with the 
proper lipid component [ 11. Anionic phospholipids 
(phosphatidylserine and phosphatidylinositol) present 
in cellular membranes are required for PKC activation. 
The enzyme-phospholipid interaction is Ca’“-depend- 
ent and a ternary non-active enzyme + Ca2+ + phos- 
pholipid complex is formed and translocated to the 
membrane. The binding of DAG (or phorbol esters) 
eventually leads through conformational changes to the 
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enzyme’s activation [4]. The binding to lipids is critical 
[4]. Epand suggests as a general rule that positively 
charged substances inhibit PKC activation, while nega- 
tively charged substances activate it [l]. 
In the present paper we report that the supernatant 
of a sonicated microsomal fraction from PHA-activated 
human PBMC contains a peptide that inhibits PKC ‘in 
vitro’, by interacting with the regulatory domain of the 
enzyme. 
In ‘in vivo tests’, the peptide inhibits particulate PKC 
in PHA-activated PBMC, but is ineffective in TPA- 
activated cell cultures. 
2. MATERIALS AND METHODS 
PBMC were isolated from healthy donors by Ficoll/Paque (Pharma- 
cia) density gradient centrifugation [5]. PBMC were suspended at 
1 x IO6 cells/ml m lscove Dulbecco modified medium (Gibco) supple- 
mented with 10% fetal calf serum (FCS) (Gibco). 100 U/ml penicillin 
and 100 U/ml gentamycm and were incubated at 37°C in 5% CO2 
humidified atmosphere. TPA (Sigma) and PHA (Burroughs 
Wellcome) were administered at 50 @ml and 1 &ml. respectively. 
2.2. Protein kinuse C activltj 
Cytosolic and particulate PKC were partially purified by DEAE- 
cellulose (Whatman) chromatography as already reported [6-81. PKC 
activity was assayed by a modification of the procedure of Kishimoto 
et al. [9] according to Mellom et al. [lo], using histone III S (Sigma) 
as a substrate. One unit of PKC activity was defined as the amount 
that causes the mcorporation of 1 nmol of [3’P]ATP (300 CYmmol) 
(Amersham) in the substrate under the experimental conditions. Pro- 
tamine (Sigma) was also tested as a substrate at a 0.01. 0.1 and 1 pg 
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concentration. Protein kinase A activity was measured according to 
Sullivan et al. [23] using casein II (Sigma) as a substrate. 
2.3. Preparation of SptMF 
PBMC were suspended in 0.25 M sucrose, 1 mM EDTA and 1 mM 
leupeptin at a density of 100 x lo6 cells/ml and disrupted in a glass- 
Teflon homogenizer. After a series of 50 strokes the percentage of 
intact cells was monitored under the microscope. The procedure was 
stopped when intact cells were less than 5%. The subcellular fractions 
were separated by initial centrifugation at 600 x g for 10 min. Superna- 
tant I was collected and centrifuged at 12,000 x g for 10 min, superna- 
tant II centrifuged at 100,000 x g for 1 h. The pellet (microsomal 
fraction) was resuspended in 1 ml of 0.25 M sucrose and 1 mM EDTA, 
sonicated (one pulse for 10 s) and centrifuged again at 100,000 x g for 
1 h. The supernatant III, SptMF, that appeared to be perfectly clear, 
was boiled for 45 min. Protein determination was performed accord- 
ing to Bradford [l 1] using bovine serum albumin as a standard. Aliq- 
uots corresponding to about 75-80 ng of protein were added to 
50 x lo6 PHA activated PBMC and particulate PKC was tested after 
30 min. 
2.4. Ion-exchange chromatography 
500 ,~l of SptMF containing approximately 150 fig protein, were 
loaded onto a Pl l-cellulose phosphate (Whatman) column (0.5 x 2.5 
cm) (previously equilibrated with 5 ml of 0.5 M sodium acetate pH 6 
and 10 ml of 0.05 M sodium acetate pH 6) and adsorbed proteins were 
eluted with a 20 ml linear l-2 M NaCl gradient. The fractions (1 ml 
each) were concentrated by Amicon Microconcentrators- to approxi- 
mately 500 ~1 and collected in 0.05 M sodium acetate. 100 ~1 of each 
fraction were tested on one unit of cytosolic semipurified PKC. The 
fractions carrying inhibitory activity contained from 8 to 12 ng of 
protein. In the particulate PKC assay, the remaining 400 ~1 of inhib- 
iting fraction (40-50 ng of protein) were added to 50 x lo6 PHA- 
activated PBMC. 
2.5. Trypsin digestion 
The inhibiting activity of eight different IN preparations from the 
same donor was tested on semipurified PKC before and after trypsin 
treatment (1 mg/ml, 2 h at 37°C). Trypsin (1 mg/ml) + soybean (20 
&ml) (Gibco) were added to semipurified cytosolic PKC as control 
of trypsin-treated IN samples. 
2.6. Mild-hydrolysis of protein kinase C with trypsin 
DEAE-cellulose semipurified PKC was partially digested with 1 
mg/ml of trypsin (Sigma) for 10 min at 37°C to cleave the regulatory 
domain. The digestion was stopped by the addition of bovine serum 
albumin 10 mg/ml. The digested PKC was stored at 4°C and used 
within one hour. 
2.7. SDS-polyacrylamide gel electrophoresis 
Electrophoretic analysis of the active fraction was performed in 
SDS-polyacrylamide gel electrophoresis (15% acrylamide) under 
standard conditions [12] and stained by the Silver assay [12]. In some 
experiments /7-MSH was removed from the electrophoretic sample 
buffer. 
3. RESULTS 
3.1. Isolation of PKC inhibitor from PHA-activated 
PBMC microsomes 
After sonication of the microsomal preparation and 
centrifugation at 100,000 x g, the obtained supernatant, 
SptMF, contained a factor capable of inhibiting the 
activity of particulate PKC translocated to the mem- 
brane of PHA-activated PBMC. In several experiments 
the mean particulate PKC activity in PHA-activated 
PBMC treated with SptMF was significantly lower than 
Table I 
Inhibitory effect of heated SptMF on particulate PKC 
Treatment Particulate PKC (U) 
PHA-activated PBMC 1.56 f 0.25 
Same, plus heated SptMF 0.38 f 0.11 
In 13 experiments particulate PKC values from PHA-activated PBMC 
cultures (50 x lo6 cells) were compared to PHA-activated PBMC cul- 
tures to which 75 ng SptMF had been added. Mean and S.E. are 
presented (P < 0.001). 
PKC values obtained in PHA-activated cultures to 
which SptMF was not added (Table I). The degree of 
inhibition ranged from 18% to 100%. SptMF which had 
not been previously boiled was inactive on particulate 
PKC. The inhibitory activity of SptMF was completely 
retained by a PC-l 1 chromatographic olumn and re- 
covered by elution with a linear l-2 M NaCl gradient. 
Peak activity was detected between 1.35-l .50 M NaCl. 
3.2. Molecular properties of the inhibitory factor (IN) 
Tryptic digestion of active fractions on semipurified 
cytosolic PKC removes the inhibitory activity, suggest- 
ing that the inhibitory factor (IN) is a protein (Table II). 
From an average 100 million cells 8-12 ng of IN were 
obtained. 
Ultrafiltration with 3,000 M.W. cut-off Amicon fil- 
ters, completely retained the activity, while it passed 
through filters with a 10,000 M.W. cut-off, indicating 
that the active protein M.W. was between 3,000 and 
10,000 M.W. SDS-gel electrophoresis of the fractions 
eluted from the PC1 1 column, exhibiting the highest 
PKC inhibitory activity showed a single band of ap- 
proximately 1,500 Da (Fig. la). This result contradicts 
the experiments indicating that the inhibitory activity 
was retained by a filter with a 3,000 M.W. cut-off. When 
/I-MSH was removed from the electrophoretic sample 
buffer a fuzzy, single band was observed at about 6,500 
M.W. (Fig. lb). These results indicate that in its native 
form IN is an oligomeric protein and that j?-MSH 
cleaves the disulfide bridges that keep the subunits to- 
gether. /I-MSH is also present in the DEAE elution 
Table II 
Effect of trypsin digestion on the inhibitory effect of IN on DEAE- 
cellulose semipurified PKC 
Treatment PKC (U) 
Native After trypsin digestion 
Control 1.45 1.58 
IN 0.78 f 0.02 1.30 f 0.03 
(inhibition = 46%) (inhibition = 17%) 
PKC was assayed prior (‘native’) and after trypsin treatment. IN: 
active fraction eluted from Pl l-cellulose phosphate column. The data 
exposed are the mean values f S.E. of 8 experiments. For details see 
the experimental section. 
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Fig. 1. Silver-staining of SDS-polyacrylamide gel electrophoresis of 
IN. (A) Under standard conditions; (B) without B-MSH. The active 
fraction eluted from the Pll-cellulose phosphate column was em- 
ployed. 
buffer of semipurified PKC and therefore might be re- 
sponsible for the transformation of the native IN (6,500 
M.W.) to the 1,500 M.W. The inhibitory activity of IN 
‘in vitro’ was studied in a dose-dependent experiment. 
A linear increase of inhibition from 0 to 85% of PKC 
activity was observed, up to 24 ng of IN. Higher doses 
up to 40 ng did not essentially increase the inhibition 
(Fig. 2). 
3.3. Inhibitory properties of IN 
IN does not significantly affect cyclic-AMP-depend- 
ent kinase (PKA) (Fig. 2). Inhibition of DEAE-cellulose 
semipurified PKC was investigated following two main 
approaches. (1) The use of protamin. This substrate 
does not require Ca” or PL and is phosphorylated by 
PKC without the activation of the regulatory domain 
[13]. In this case IN was ineffective (Table IIIA). (2) 
Mild hydrolysis of PKC with trypsin that cleaves the 
regulatory domain and generates Ca2’- and PL-inde- 
pendent enzymatic activity. After mild trypsinization of 
PKC, IN was ineffective on the Ca2’- and PL-independ- 
ent activity. The tryptic digestion was interrupted when 
Ca2’- and PL-dependent PKC activity was equivalent 
to the Ca2’- and PL-independent activity. TPA may 
substitute for DG and the IN activity was not modified 
(data not shown). When PS and DG were removed from 
the reaction mixture the percentage of PKC inhibition 
by IN was unmodified. When Ca2+ was omitted from 
the reaction no significant PKC inhibition was ob- 
served, suggesting that at least 5 mM Ca*’ was required 
for IN activity (Fig. 3). A gradual increase of the sub- 
n PKA 
q PKC 
I I I I I I I I I I 
4 8 12 16 20 24 26 32 36 40 ng 
Fig. 2. Effect of increasing concentrations of IN on PKA and PKC 
activities. The DEAE-cellulose semipurified PKC, and the IN prepa- 
ration after Pl l-cellulose phosphate chromatography were employed. 
Data are expressed as % of control PKC activity, and are the mean 
of three expenments. 
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Ca” + + + + + + _ . 
PS + + - _ + + ++ 
DG + + + + - . ++ 
IN + - + -L.. + 
lnhlblllon % 52 54 46 20 
Fig. 3. Effects of different cofactors on PKC activity in the presence 
of IN (8-12 ng protein). The data shown are the mean of three exper- 
iments. The same preparations of PKC and IN as specified in Fig. 2 
were employed. 
strate histone III S up to 3x (1.5 mg/ml) did not modify 
the degree of IN inhibition of PKC activity in vitro. 
When IN was added to PHA-activated PBMC cultures 
particulate PKC activity was significantly reduced. 
However, particulate PKC activity in TPA-activated 
PBMC was unaffected. 
4. DISCUSSION 
Our data demonstrate that the SptMF of stimulated 
human PBMC contains a factor capable of inhibiting 
PKC activity ‘in vitro’ and ‘in vivo’ (IN). IN is not 
active against the c-AMP-dependent protein kinase in- 
dicating that the inhibitory effect is specific and not due 
to the presence of unidentified charged compounds that 
may exert an inhibitory action on PKC translocated to 
the membrane [l]. The IN is eluted from PC11 at an 
NaCl concentration of 1.35-l .50 in an oligomeric form; 
as demonstrated by SDS-gel electrophoresis, fi-MSH in 
the sample buffer cleaves the native form in lower mo- 
lecular weight subunits. The native form is less efficient 
than the subunits as inhibitor of cytosolic PKC activity, 
though it is completely efficient on particulate PKC. 
Disulfide bridges present in IN raise the question of 
whether these groups form disulfide bridges with the 
cysteine-rich region of the regulatory domain of PKC. 
IN does not belong to the class of pseudosubstrate 
peptides, as it is not active on the enzyme’s catalytic site 
and it is specific for PKC [16]. At least four sets of data 
are in favour of a specific interaction of IN with the 
enzyme’s regulatory domain after Ca*’ binding: (1) the 
lack of inhibition of the activity generated by mild tryp- 
tic hydrolysis of PKC without Ca2’ and PL; (2) unsuc- 
cessful inhibition of protamine phosphorylation by 
PKC; (3) the failure to inhibit the activity of PKC 
translocated to the membrane by TPA; (4) the permis- 
sive role of Ca2+ binding to the regulatory domain for 
the IN induced PKC inhibition. 
Preparation of IN from resting PBMC has been un- 
successful. Cycloheximide treatment (15 pg/ml) [ 141 has 
no effect. The finding suggests that IN is constitutively 
preformed in PBMC and that PHA treatment induces 
post-translational modification that activates IN. IN is 
stabilized by heating. The prolonged heating step (45 
min) was found necessary to remove other heat stable 
protein contaminants from the preparations. The very 
high stability of the peptide during heating could be 
explained on the basis of its low molecular mass which 
probably allows a rapid recovery of the active form of 
the protein molecule. 
A number of PKC inhibitors have been reported in 
the literature, but none of them has properties and char- 
Table III 
Effect of IN on the activity of PKC under different conditions: (A) in 
the presence of histone III S or protamine as PKC substrates; (B) after 
mild tryptic digestion of PKC 
A 
Substrate PKC (U) 
Without IN With IN Inhibition (%) 
Histone III S 1.86 1.17 37 
Protamine 
(0.01 ng/ 0.20 0.17 _ 
ml) 
B 
Treatment PKC (U) 
Before tryptic After tryptic digestion 
digestion 
Plus Ca*+ Minus Ca2’ 
and PL and PL 
Control 0.63 0.12 0.08 
IN 0.40 0.08 
(inhibition = 37%) (inhibition = 0) 
The DEAE-cellulose semipurified PKC and the IN preparation after 
Pl l-cellulose phosphate chromatography were employed. The data 
shown correspond to the highest PKC activity detected. The data 
shown are the mean of three experiments. For details see section 2. 
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acteristics comparable to those of IN [15-241. IN is a 
constitutive peptide found in microsomal vesicles. Pre- 
sumably it may become available in other cellular com- 
partments and in the cytosol can exert its effect on the 
regulatory domain of translocated PKC, on the cy- 
tosolic side of the membrane lipid bilayer. IN can pene- 
trate the cell membrane and reach the cytosolic face of 
the membrane, but the mechanism of penetration across 
the cell membrane remains to be investigated. IN does 
not prevent PKC activation and it becomes fully effec- 
tive only after the binding of Ca” to the regulatory 
domain, IN appears therefore to be a true ‘physiological 
modulator’ of PKC activity. 
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